{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:21:47Z","timestamp":1777522907639,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T00:00:00Z","timestamp":1376438400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T00:00:00Z","timestamp":1376438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (<jats:italic>Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia<\/jats:italic>). We conducted a retrospective cohort study to evaluate risk factors for new-onset acute kidney injury (AKI) in critically ill patients receiving high intravenous doses of colistin methanesulfonate and\/or other nephrotoxic antibiotics.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>The cohort consisted of 279 adults admitted to two general ICUs in teaching hospitals between 1 April 2009 and 30 June 2011 with 1) no evidence on admission of acute or chronic kidney disease; and 2) treatment for more than seven days with CMS and\/or other nephrotoxic antimicrobials (NAs, that is, aminoglycosides, glycopeptides). Logistic regression analysis was used to identify risk factors associated with this outcome.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>The 279 cases that met the inclusion criteria included 147 patients treated with CMS, alone (n = 90) or with NAs (n = 57), and 132 treated with NAs alone. The 111 (40%) who developed AKI were significantly older and had significantly higher Simplified Acute Physiology Score II (SAPS II) scores than those who did not develop AKI, but rates of hypertension, diabetes mellitus and congestive heart failure were similar in the two groups. The final logistic regression model showed that in the 147 patients who received CMS alone or with NAs, onset of AKI during the ICU stay was associated with septic shock and with SAPS II scores \u226543. Similar results were obtained in the 222 patients treated with CMS alone or NAs alone.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>In severely ill ICU patients without pre-existing renal disease who receive CMS high-dose for more than seven days, CMS therapy does not appear to be a risk factor for this outcome. Instead, the development of AKI was strongly correlated with the presence of septic shock and with the severity of the patients as reflected by the SAPS II score.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/cc12853","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T18:30:48Z","timestamp":1376505048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and\/or other nephrotoxic antibiotics: a retrospective cohort study"],"prefix":"10.1186","volume":"17","author":[{"given":"Monica","family":"Rocco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Montini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Alessandri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Laderchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"De Gennaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giammarco","family":"Raponi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Pietropaoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,14]]},"reference":[{"key":"2088_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1086\/499819","volume":"42","author":"GH Talbot","year":"2006","unstructured":"Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG: Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.\n                           Clin Infect Dis 2006, 42: 657-668. 10.1086\/499819","journal-title":"Clin Infect Dis"},{"key":"2088_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijantimicag.2004.10.001","volume":"25","author":"J Li","year":"2005","unstructured":"Li J, Nation RL, Milne R, Turnindge J, Coulthard K: Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.\n                           Int J Antimicrob Agents 2005, 25: 11-25. 10.1016\/j.ijantimicag.2004.10.001","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 2","key":"2088_CR3","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1086\/504485","volume":"43","author":"PK Linden","year":"2006","unstructured":"Linden PK, Paterson DL: Parenteral and inhaled colistin for the treatment of ventilator-associated pneumonia.\n                           Clin Infect Dis 2006,43(Suppl 2):S89-94.","journal-title":"Clin Infect Dis"},{"key":"2088_CR4","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1128\/AAC.49.11.4814-4815.2005","volume":"49","author":"J Li","year":"2005","unstructured":"Li J, Rayner CR, Nation RL, Deans A, Boots R, Widdecombe N, Douglas A, Lipman J: Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration.\n                           Antimicrob Agent Chemother 2005, 49: 4814-4815. 10.1128\/AAC.49.11.4814-4815.2005","journal-title":"Antimicrob Agent Chemother"},{"key":"2088_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.clinthera.2008.01.015","volume":"30","author":"N Markou","year":"2008","unstructured":"Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, Rafailidis P, Apostolakos H, Baltopoulos P: Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open label, uncontrolled study.\n                           Clin Ther 2008, 30: 143-151. 10.1016\/j.clinthera.2008.01.015","journal-title":"Clin Ther"},{"key":"2088_CR6","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/cc2872","volume":"8","author":"R Bellomo","year":"2004","unstructured":"Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, the Acute Dialysis Quality Initiative workgroup: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.\n                           Crit Care 2004, 8: R204-R212. 10.1186\/cc2872","journal-title":"Crit Care"},{"key":"2088_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J Struelens MJ, Vatopoulos A, Weber JT, Monnet DL: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.\n                           Clin Microbiol Infect 2012, 18: 268-281. 10.1111\/j.1469-0691.2011.03570.x","journal-title":"Clin Microbiol Infect"},{"key":"2088_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000322161","volume":"31","author":"F Garzotto","year":"2011","unstructured":"Garzotto F, Piccinni P, Cruz D, Gramaticopolo S, Dal Santo M, Aneloni G, Kim JC, Rocco M, Alessandri E, Giunta F, Michetti V, Iannuzzi M, Belluomo Anello C, Brienza N, Carlini M, Pelaia P, Gabbanelli V, Ronco C, NEFROINT investigation group: RIFLE-based data collection\/management system applied to a prospective cohort multicenter Italian study on the epidemiology of acute Kidney injury in the intensive care unit.\n                           Blood Purif 2011, 31: 159-171. 10.1159\/000322161","journal-title":"Blood Purif"},{"key":"2088_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa067373","volume":"358","author":"JA Russell","year":"2008","unstructured":"Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presnell JJ, Ayers D, VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock.\n                           N Engl J Med 2008, 358: 877-887. 10.1056\/NEJMoa067373","journal-title":"N Engl J Med"},{"key":"2088_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","volume":"171","author":"American Thoracic Society","year":"2005","unstructured":"American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with Hospital acquired, ventilator-associated, and Healthcare-associated pneumonia.\n                           Am J Respir Crit Care Med 2005, 171: 388-416.","journal-title":"Am J Respir Crit Care Med"},{"key":"2088_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/0003-4819-141-4-200408170-00011","volume":"141","author":"P Dodek","year":"2004","unstructured":"Dodek P, Keenan S, Cook D, Heyland D, Jacka M, Hand L, Muscedere J, Foster D, Mehta N, Hall R, Bruin Buisson C, Canadian Critical Care Trials Group, Canadian Critical Care Society: Evidence-based clinical practice guidelines for the prevention of ventilator-associated pneumonia.\n                           Ann Intern Med 2004, 141: 305-313. 10.7326\/0003-4819-141-4-200408170-00011","journal-title":"Ann Intern Med"},{"key":"2088_CR12","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1128\/AAC.01361-08","volume":"53","author":"D Plachouras","year":"2009","unstructured":"Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H: Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram negative bacteria.\n                           Antimicrob Agents Chemother 2009, 53: 3430-3436. 10.1128\/AAC.01361-08","journal-title":"Antimicrob Agents Chemother"},{"key":"2088_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","volume":"6","author":"J Li","year":"2006","unstructured":"Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL: Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.\n                           Lancet Infect Dis 2006, 6: 589-601. 10.1016\/S1473-3099(06)70580-1","journal-title":"Lancet Infect Dis"},{"key":"2088_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2165\/00003088-200746120-00003","volume":"46","author":"F Pea","year":"2007","unstructured":"Pea F, Viale P, Pavan F, Furlanut M: Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.\n                           Clin Pharmacokinet 2007, 46: 997-1008. 10.2165\/00003088-200746120-00003","journal-title":"Clin Pharmacokinet"},{"key":"2088_CR15","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1128\/AAC.01149-08","volume":"53","author":"F Pea","year":"2009","unstructured":"Pea F, Furlanut M, Negri C, Pavan F, Crapis M, Cristini F, Viale PG: Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients.\n                           Antimicrob Agents Chemother 2009, 53: 1863-1867. 10.1128\/AAC.01149-08","journal-title":"Antimicrob Agents Chemother"},{"key":"2088_CR16","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1128\/AAC.40.11.2494","volume":"40","author":"JM Prins","year":"1996","unstructured":"Prins JM, Weverling GJ, de Blok K, van Ketel RJ, Speelman P: Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy.\n                           Antimicrob Agents Chemother 1996, 40: 2494-2499.","journal-title":"Antimicrob Agents Chemother"},{"key":"2088_CR17","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/cid\/cir934","volume":"54","author":"DF Florescu","year":"2012","unstructured":"Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC: What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression.\n                           Clin Infect Dis 2012, 54: 670-680. 10.1093\/cid\/cir934","journal-title":"Clin Infect Dis"},{"key":"2088_CR18","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1128\/AAC.00405-08","volume":"52","author":"M Vaara","year":"2008","unstructured":"Vaara M, Fox J, Loidl G, Siikanen O, Apajalahti J, Hansen F, Frimodt-Moeller N, Nagai J, Takano M, Vaara T: Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.\n                           Antimicrob Agents Chemother 2008, 52: 3229-3236. 10.1128\/AAC.00405-08","journal-title":"Antimicrob Agents Chemother"},{"key":"2088_CR19","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","volume":"30","author":"LM Lim","year":"2010","unstructured":"Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A III, Forrest A, Bulitta JB, Tsuji BT: Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing.\n                           Pharmacotherapy 2010, 30: 1279-1291. 10.1592\/phco.30.12.1279","journal-title":"Pharmacotherapy"},{"key":"2088_CR20","doi-asserted-by":"publisher","first-page":"R27","DOI":"10.1186\/cc3995","volume":"10","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Kasiakou SK: Toxicity of polymyxins: a systematic review of the evidence from old and recent studies.\n                           Crit Care 2006, 10: R27. 10.1186\/cc3995","journal-title":"Crit Care"},{"key":"2088_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ijantimicag.2009.11.016","volume":"35","author":"CY Cheng","year":"2010","unstructured":"Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC: Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug resistant Gram-negative bacterial infections.\n                           Int J Antimicrob Agents 2010, 35: 297-300. 10.1016\/j.ijantimicag.2009.11.016","journal-title":"Int J Antimicrob Agents"},{"key":"2088_CR22","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1128\/AAC.49.8.3136-3146.2005","volume":"49","author":"SK Kasiakou","year":"2005","unstructured":"Kasiakou SK, Michalopulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME: Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis.\n                           Antimicrob Agents Chemother 2005, 49: 3136-3146. 10.1128\/AAC.49.8.3136-3146.2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2088_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-5-1","volume":"5","author":"ME Falagas","year":"2005","unstructured":"Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A: Toxicity after prolonged (more than four weeks) administration of intravenous colistin.\n                           BMC Infect Dis 2005, 5: 1. 10.1186\/1471-2334-5-1","journal-title":"BMC Infect Dis"},{"key":"2088_CR24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ijantimicag.2009.06.028","volume":"34","author":"J Kim","year":"2009","unstructured":"Kim J, Lee K-H, Yoo S, Pai H: Clinical characteristics and risk factors of colistin-induced nephrotoxicity.\n                           Int J Antimicrob Agents 2009, 34: 434-438. 10.1016\/j.ijantimicag.2009.06.028","journal-title":"Int J Antimicrob Agents"},{"key":"2088_CR25","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1086\/599225","volume":"48","author":"JD Hartzell","year":"2009","unstructured":"Hartzell JD, Neff R, Ake R, Howard R, Olson S, Paolino K, Vishneopolsky M, Weintrob A, Wortmann G: Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.\n                           Clin Infect Dis 2009, 48: 1724-1728. 10.1086\/599225","journal-title":"Clin Infect Dis"},{"key":"2088_CR26","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/cid\/cir611","volume":"53","author":"JM Pogue","year":"2011","unstructured":"Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS: Incidence of and Risk factors for colistin-associated nephrotoxicity in a large academic health system.\n                           Clin Infect Dis 2011, 53: 879-884. 10.1093\/cid\/cir611","journal-title":"Clin Infect Dis"},{"key":"2088_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jinf.2010.11.013","volume":"62","author":"P Rattanaumpawan","year":"2011","unstructured":"Rattanaumpawan P, Ungprasert P, Thamlikitkul V: Risk factors for colistin-associated nephrotoxicity.\n                           J Infect 2011, 62: 187-190. 10.1016\/j.jinf.2010.11.013","journal-title":"J Infect"},{"key":"2088_CR28","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1128\/AAC.01707-09","volume":"54","author":"CA Deryke","year":"2010","unstructured":"Deryke CA, Crawford AJ, Uddin N, Wallace MR: Colistin dosing and nephrotoxicity in a large community teaching hospital.\n                           Antimicrob Agents Chemother 2010, 54: 4503-4505. 10.1128\/AAC.01707-09","journal-title":"Antimicrob Agents Chemother"},{"key":"2088_CR29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1155\/2008\/743197","volume":"19","author":"DM Sabuda","year":"2008","unstructured":"Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J: Utilization of colistin for treatment of multidrug-resistant\n                           Pseudomonas aeruginosa\n                           .\n                           Can J Infect Dis Med Microbiol 2008, 19: 413-418.","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2088_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/QCO.0b013e328332e672","volume":"22","author":"R Nation","year":"2009","unstructured":"Nation R, Li J: Colistin in the 21th century.\n                           Curr Opin Infect Dis 2009, 22: 535-543. 10.1097\/QCO.0b013e328332e672","journal-title":"Curr Opin Infect Dis"},{"key":"2088_CR31","doi-asserted-by":"publisher","first-page":"R14","DOI":"10.1186\/cc12484","volume":"17","author":"C Teixeira","year":"2013","unstructured":"Teixeira C, Garzotto F, Piccinni P, Brienza N, Iannuzzi M, Gramaticopolo S, Forfori F, Pelaia P, Rocco M, Ronco C, Anello CB, Bove T, Carlini M, Michetti V, Pelaia P, Cruz DN, for the NEFROlogiae Cura INTensiva (NEFROINT) investigators: Fluid balance and urine volume are independent predictors of mortality in acute kidney injury.\n                           Crit Care 2013, 17: R14. 10.1186\/cc12484","journal-title":"Crit Care"},{"key":"2088_CR32","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00134-008-1367-2","volume":"35","author":"SM Bagshaw","year":"2009","unstructured":"Bagshaw SM, Lapisky S, Dial A Arabi Y, Dodek P, Wood G, Ellis P, Guzman J, Marshall J, Parrillo JE, Skrobik Y, Kumar A, Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group: Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy.\n                           Intensive Care Med 2009, 35: 871-878. 10.1007\/s00134-008-1367-2","journal-title":"Intensive Care Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc12853.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/cc12853\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc12853.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T13:03:53Z","timestamp":1728306233000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/cc12853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,14]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,8]]}},"alternative-id":["2088"],"URL":"https:\/\/doi.org\/10.1186\/cc12853","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,14]]},"assertion":[{"value":"6 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R174"}}